Cross-source evidence timeline

Etelcalcetide research timeline

Follow 47 selected, directly cited source records from February 7, 2017 through October 31, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

47Selected records
9Source years
3Evidence lanes
October 31, 2026Latest source date

Source year

2026

10 records
  1. Literature metadata

    Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.↗

    PubMed lists PMID 36790677 in International urology and nephrology as Observational Study, Journal Article, with publication-date metadata of 2023-02-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.↗

    PubMed lists PMID 29691773 in PharmacoEconomics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-11 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia.↗

    PubMed lists PMID 42853437 in CEN case reports as Journal Article, Case Reports, with publication-date metadata of 2026-10-09 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.↗

    PubMed lists PMID 28063122 in Journal of pharmacokinetics and pharmacodynamics as Journal Article, with publication-date metadata of 2017-01-06 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy.↗

    PubMed lists PMID 41307414 in Clinical nephrology as Journal Article, Observational Study, Clinical Trial, Phase IV, with publication-date metadata of 2025 (year precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up.↗

    PubMed lists PMID 42739661 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-08-28 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina.↗

    PubMed lists PMID 39557587 in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy as Journal Article, Observational Study, Multicenter Study, with publication-date metadata of 2024-11-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT03969329↗

    PeptideScanner retained ClinicalTrials.gov record NCT03969329 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  9. Literature metadata

    Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation.↗

    PubMed lists PMID 39081745 in Kidney international reports as Journal Article, with publication-date metadata of 2024-04-04 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT03633708↗

    PeptideScanner retained ClinicalTrials.gov record NCT03633708 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

Source year

2024

5 records
  1. Literature metadata

    Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis.↗

    PubMed lists PMID 30013296 in P & T : a peer-reviewed journal for formulary management as Journal Article, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.↗

    PubMed lists PMID 29719376 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2018-04-19 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.↗

    PubMed lists PMID 28615947 in Therapeutics and clinical risk management as Journal Article, Review, with publication-date metadata of 2017-06-01 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.↗

    PubMed lists PMID 29440923 in International journal of nephrology and renovascular disease as Journal Article, Review, with publication-date metadata of 2018-02-05 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Acute and Severe Hypercalcemia Early After Kidney Transplantation in a Patient Previously Treated With Etelcalcetide.↗

    PubMed lists PMID 37383843 in Transplant international : official journal of the European Society for Organ Transplantation as Journal Article, with publication-date metadata of 2023-06-13 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2023

4 records
  1. Literature metadata

    Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.↗

    PubMed lists PMID 38050530 in Cureus as Journal Article, with publication-date metadata of 2023-11-02 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial).↗

    PubMed lists PMID 33305109 in Kidney international reports as Journal Article, with publication-date metadata of 2020-09-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT03960437↗

    PeptideScanner retained ClinicalTrials.gov record NCT03960437 at 2026-11-15T22:07:29.454Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  4. Literature metadata

    Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation.↗

    PubMed lists PMID 36611532 in Healthcare (Basel, Switzerland) as Journal Article, with publication-date metadata of 2022-12-26 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2022

3 records
  1. Literature metadata

    A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.↗

    PubMed lists PMID 34787825 in CEN case reports as Case Reports, Journal Article, with publication-date metadata of 2021-11-17 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT03795558↗

    PeptideScanner retained ClinicalTrials.gov record NCT03795558 at 2026-11-15T22:07:29.454Z. Its registry update date was 2022-03-23, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  3. Literature metadata

    Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis.↗

    PubMed lists PMID 33825489 in Circulation research as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-07 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2021

3 records
  1. Literature metadata

    Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathy…↗

    PubMed lists PMID 28867373 in Bone as Journal Article, with publication-date metadata of 2017-09-01 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology.↗

    PubMed lists PMID 31853791 in Journal of nephrology as Journal Article, Practice Guideline, with publication-date metadata of 2019-12-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT03299244↗

    PeptideScanner retained ClinicalTrials.gov record NCT03299244 at 2026-11-15T22:07:29.454Z. Its registry update date was 2021-04-30, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

Source year

2020

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT03283098↗

    PeptideScanner retained ClinicalTrials.gov record NCT03283098 at 2026-11-15T22:07:29.454Z. Its registry update date was 2020-02-10, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

Source year

2019

13 records
  1. Literature metadata

    Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.↗

    PubMed lists PMID 27639083 in CPT: pharmacometrics & systems pharmacology as Journal Article, with publication-date metadata of 2016-09-17 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Etelcalcetide for the treatment of secondary hyperparathyroidism.↗

    PubMed lists PMID 28277829 in Expert opinion on pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-03-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.↗

    PubMed lists PMID 28508378 in Clinical pharmacokinetics as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-01 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].↗

    PubMed lists PMID 29786181 in Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia as Practice Guideline, Journal Article, with publication-date metadata of 2018-05 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Dramatic Regression of Parathyroid Gland Swelling After Conversion of Calcimimetic Medication From Cinacalcet to Etelcalcetide.↗

    PubMed lists PMID 29927050 in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy as Case Reports, Letter, with publication-date metadata of 2018-06-21 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?↗

    PubMed lists PMID 30009474 in Seminars in dialysis as Editorial, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-07-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Formulary Drug Review: Etelcalcetide.↗

    PubMed lists PMID 29276237 in Hospital pharmacy as Journal Article, Review, with publication-date metadata of 2017-09-25 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT01785849↗

    PeptideScanner retained ClinicalTrials.gov record NCT01785849 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT01788046↗

    PeptideScanner retained ClinicalTrials.gov record NCT01788046 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-08-20, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT01896232↗

    PeptideScanner retained ClinicalTrials.gov record NCT01896232 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-18, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT02833857↗

    PeptideScanner retained ClinicalTrials.gov record NCT02833857 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-10, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  12. Literature metadata

    Parsabiv Could Be Pricey Addition In Care for CKD, ESRD Patients.↗

    PubMed lists PMID 28661841 in Managed care (Langhorne, Pa.) as Journal Article, with publication-date metadata of 2017-06 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  13. Clinical trials

    ClinicalTrials.gov record NCT01785875↗

    PeptideScanner retained ClinicalTrials.gov record NCT01785875 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-04-10, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

Source year

2018

3 records
  1. Regulatory

    Federal Register notice 2018-28221↗

    The Federal Register published notice 2018-28221, attributed to FDA and its parent HHS department, on 2018-12-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV,” and PeptideScanner's exact reviewed identity mapping connects the document to Etelcalcetide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01932970↗

    PeptideScanner retained ClinicalTrials.gov record NCT01932970 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-10-17, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01134562↗

    PeptideScanner retained ClinicalTrials.gov record NCT01134562 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-01-02, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

Source year

2017

5 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02102204↗

    PeptideScanner retained ClinicalTrials.gov record NCT02102204 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-11-17, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01134549↗

    PeptideScanner retained ClinicalTrials.gov record NCT01134549 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01254565↗

    PeptideScanner retained ClinicalTrials.gov record NCT01254565 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT01414114↗

    PeptideScanner retained ClinicalTrials.gov record NCT01414114 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  5. Regulatory

    Drugs@FDA application NDA208325↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 208325 with status AP dated 2017-02-07, and names etelcalcetide among the application record's active ingredients.↗